Caprine brucellosis: A historically neglected disease with significant impact on public health

Carlos A. Rossetti¹*, Angela M. Arenas-Gamboa², Estefanía Maurizio¹

¹ Instituto de Patobiología, CICVyA-CNIA, INTA. Nicolás Repetto y de Los Reseros s/n, Hurlingham, Buenos Aires, Argentina, ² Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, United States of America

* rossetti.carlos@inta.gob.ar

Abstract

Caprine brucellosis is a chronic infectious disease caused by the gram-negative cocci-bacillus Brucella melitensis. Middle- to late-term abortion, stillbirths, and the delivery of weak offspring are the characteristic clinical signs of the disease that is associated with an extensive negative impact in a flock’s productivity. B. melitensis is also the most virulent Brucella species for humans, responsible for a severely debilitating and disabling illness that results in high morbidity with intermittent fever, chills, sweats, weakness, myalgia, abortion, osteoarticular complications, endocarditis, depression, anorexia, and low mortality. Historical observations indicate that goats have been the hosts of B. melitensis for centuries; but around 1905, the Greek physician Themistokles Zammit was able to build the epidemiological link between “Malta fever” and the consumption of goat milk. While the disease has been successfully managed in most industrialized countries, it remains a significant burden on goat and human health in the Mediterranean region, the Middle East, Central and Southeast Asia (including India and China), sub-Saharan Africa, and certain areas in Latin America, where approximately 3.5 billion people live at risk. In this review, we describe a historical evolution of the disease, highlight the current worldwide distribution, and estimate (by simple formula) the approximate costs of brucellosis outbreaks to meat- and milk-producing farms and the economic losses associated with the disease in humans. Successful control leading to eradication of caprine brucellosis in the developing world will require a coordinated Global One Health approach involving active involvement of human and animal health efforts to enhance public health and improve livestock productivity.

Author summary

Human brucellosis is an ancient disease that has had different names throughout time based on the main clinical symptom (fever) and the geographical location: Malta fever, Mediterranean fever, Undulant fever, Gibraltar fever, Rock fever, and Neapolitan fever, among others. Retrospective studies have demonstrated that goats have been the hosts of B. melitensis for centuries, with evidence of its zoonotic potential early in evolution. Since
domestication of goats (and also sheep), the incidence of human brucellosis has been on the rise, becoming endemic in resource-limited settings. Today, millions of goats and approximately half of the human population worldwide live at risk. For that reason, more effective prevention and control measures, such as affordable vaccines, more sensitive and specific diagnostic techniques, and the control livestock movement, among others, are desperately needed to control and eradicate brucellosis in goats and to prevent human brucellosis.

Introduction

*Brucella melitensis* is the etiological agent of caprine brucellosis, an infectious zoonotic disease with significant economic impact on both the livestock industry and public health. Worldwide, there are approximately 1 billion goats, with an increase of the population by more than 20% in the last 10 years. Approximately 90% of goats are located in the developing world, where they are considered one of the most important sources of protein for humans [1]. Caprine brucellosis has been controlled in most industrialized countries; however, this disease remains endemic in resource-limited settings, where small ruminants are the major livestock species and the main economical livelihood, such as the Mediterranean region, the Middle East, Central Asia, sub-Saharan Africa, and parts of Latin America [2]. Among the different *Brucella* spp. capable of causing disease in humans (*B. abortus, B. melitensis, B. canis* and *B. suis*), *B. melitensis* is the most virulent [3]. Human brucellosis has had different names throughout time based on the main clinical symptom (fever) and the geographical location: Malta fever, Mediterranean fever, Undulant fever, Gibraltar fever, Rock fever, and Neapolitan fever, among others [4]. Brucellosis is considered a severely debilitating and disabling illness that results in high morbidity with intermittent fever, chills, sweats, weakness, myalgia, abortion, osteoarticular complications, endocarditis, depression anorexia, and low mortality. Due to causing a protracted, incapacitating disease with minimal mortality, the low infectivity dose required to cause infection (10–100 colony-forming units), and the potential for aerosol dissemination, *B. melitensis* was considered a potential bioterrorist agent early in the 20th century [5]. Gradually, biological warfare moved on, and *Brucella’s* perceived status as a potential agent of bioterrorism declined, until the World Trade Center attack in 2001 brought bioterrorism back to the public’s attention. Nowadays, *B. melitensis* possession and use is still strictly regulated in the United States of America, Canada, and some European countries. Conversely, more than half a million new brucellosis cases per year occur naturally in the populations of developing areas of the world, a number which is thought to be severely underestimated [6].

Methods

A MEDLINE (via Pubmed) and SCOPUS online databases search for articles with “*Brucella melitensis*” or “brucellosis” and “goats” or “small ruminants” as keywords with no date limit and published up to December 31st, 2016, was performed. An additional internet search was done in Google without language restriction, using those terms and including country names. Early reports were obtained from original printouts from the reference list of selected articles and printed books.

Historical evolution

Despite the first scientific evidence that goats were the reservoir host of *B. melitensis* in 1905, several observations would indicate that goats have been the host of *B. melitensis* for centuries.
Phylogenetic studies suggest that brucellosis in goats emerged in the past 86,000 to 296,000 years through contact with infected sheep [8]. Interestingly, to support this observation, a recent study found lesions in vertebral bodies of an *Australopithecus africanus* (who lived 2.5 million years ago) consistent with brucellosis, where the source of infection could be the consumption of infected tissues from wild animals [9]. Subsequently, the closer association of humans with goats (and also sheep) due to domestication around 10,000 years ago [10] favored an increase in the incidence of human brucellosis. As essential resources for human survival, goat and sheep herds moved along with human communities from the Fertile Crescent in Southwestern Asia to lands around the Mediterranean Sea [11], where Phoenician traders might have contributed to the spread of *B. melitensis* infection throughout the Mediterranean littoral and islands during the first millennium B.C. [12]; it was then introduced to the Americas around the 16th century by Spanish and Portuguese conquerors [11,13].

The first written evidence of goat brucellosis could be inferred from the first description of 2 human cases of brucellosis. In the 4th century B.C., in his *Epidemics* book, Hippocrates II described 2 cases of a 120-day fever in people living in the Mediterranean littoral, most likely associated with the consumption of raw milk or derivatives of *B. melitensis*-infected sheep or goats [14]. Another testimony of the ancient presence of caprine brucellosis comes from preserved evidence from the volcanic eruption of Mount Vesuvius in Italy on August 25th in the year 79 A.D. Scanning electron microscopy examination of remnants of carbonized cheeses revealed coccilike forms consistent with *B. melitensis*, while an anthropological examination of human skeletal remains from that incident revealed an arthritic condition consistent with brucellosis [7]. References to and vivid descriptions of clinical cases compatible with human brucellosis were continuously reported in histories of military campaigns and hospital reports [15]. However, the identification of the etiological agent, the reservoir, and the epidemiology of the disease was not unraveled until the second half of the 19th century, when the British government decided to find a solution for their troops stationed on the island of Malta that annually suffered substantial losses caused by the so-called “Malta fever.” In 1859, British Army surgeon Jeffery Marston contracted what he called “Mediterranean remittent fever” [16]. After recovering, he described his own case in great detail, being the first author to clinically and pathologically differentiate human brucellosis from typhus, typhoid, and other prevalent fevers [15]. In 1884, the Australian-born British physician David Bruce was deployed to Malta to investigate the cause of “Malta fever” (later called brucellosis in his honor). Late in 1886, using a microscope, he observed a great number of micrococci in a fresh preparation of the splenic pulp of soldiers who had died from the disease [17]. One year later, Sir Bruce isolated the causative agent of “Malta fever” (which he called *Micrococcus melitensis* and then renamed *Brucella melitensis*) from samples of spleens of 4 patients inoculated into Koch’s nutrient agar and was able to reproduce the disease in monkeys following Koch’s postulates [18]. A few years later, Professor Almroth Edward Wright developed a serum agglutination test and demonstrated the presence of specific agglutinins in the blood of infected patients, which helped differentiate those who suffered “brucellosis” from those with typhoid (cholera) or malarial fever [19]. The use of this serological test in goats provided the first insights into the epidemiology of the disease. In 1904, a Public Health Officer of Malta discovered that the blood of goats that supplied milk to people that had contracted “Malta fever” had agglutinins against *M. melitensis*, and a posterior survey indicated that around 50% of Malta’s goats’ blood reacted to this microorganism. This observation suggested that goats were susceptible to natural infection with *M. melitensis*. Based on all knowledge available on brucellosis, the Greek physician Themistokles Zammit hypothesized that goats were susceptible to Malta fever and that the disease spread from goats to human. To test his hypothesis, Zammit fed seronegative, healthy goats with agar cultures of *M. melitensis* mixed into their food. Goats became seropositive to *M.
melitensis after 20 days or more, and Brucella was isolated from the milk, blood, and urine of infected animals without any clinical manifestation of the disease [20]. This simple assay demonstrated that goat milk was the disseminating vehicle of the bacteria, rather than an insect vector, and helped to build the epidemiological link of “Malta fever” to the consumption of this product. This observation was further confirmed after its ban from the diet of the Malta garrison significantly reduced the incidence of brucellosis in the army and naval forces compared to the general population of Malta that continued to consume contaminated dairy products. Later on, in 1918, Alice Evans demonstrated the similar characteristics between the M. melitensis and the etiological agent of bovine epizootic abortion, the “abortus bacillus” (now Brucella abortus), isolated by a Danish veterinarian Bernhard Bang in 1896, and based on that, both agents were included under the same bacterial genus (Brucella) in honor of David Bruce, in 1920. Major events of caprine brucellosis and its relationship with public health throughout history are summarized in Table 1.

World distribution

Caprine brucellosis refers to goat herds infected with B. melitensis. Goats can be susceptible to B. abortus infection [22,23,24] under particular epidemiological situations (for instance, when goats live in close contact with B. abortus-infected cattle); however, these individuals don’t sustain the infection in the herd. Similarly, B. suis isolations from goats have seldom been reported, but in recent times, they have not been further documented [25]. B. melitensis comprises 3 biovars (1–3), distinguished solely by their immunochemical reactions with monospecific anti-lipopolysaccharide (LPS) A- and M-determinant sera [26,27]. Available information indicates that most infections are caused by biovars 1 and 3 [28], both of which seem to have similar virulence for goats and humans.

Prevalence of caprine brucellosis around the world has been reported and referenced by others [28,29,30,31,32]. The disease is present in 5 out of the 7 continents (South and North America, Europe, Asia, and Africa). Despite being under control in most industrialized countries, it remains a major problem in the Mediterranean region, the Middle East, Central and Southeast Asia, sub-Saharan Africa, and parts of Latin America (Fig 1).

As expected, prevalence of human brucellosis is also high in those regions where goat brucellosis occurs [6]. The disease has been historically underreported, probably because low-income countries prioritize other diseases or lack facilities, human capabilities, and/or specific

| Year  | Who                                    | What                                                                 | Reference |
|-------|----------------------------------------|----------------------------------------------------------------------|-----------|
| 9th to 7th centuries B.C. | Neolithic population | Initial domestication of goats in the Fertile Crescent (Asia), evidence for the milking of goats | [11]      |
| 400 B.C. | Hippocrates II | First clinical description of human brucellosis | [14]      |
| 79 | N/A | Human skeletons with arthritic condition consistent with brucellosis | [7]       |
| 1859 | Jeffery Marston | First author to differentiate human brucellosis from other prevalent fevers | [16]     |
| 1887 | David Bruce | Isolated the causative agent of “Malta fever” (Micrococcus melitensis) for the first time and reproduced the disease in monkeys | [18]     |
| 1904 | Anonymous Public Health Officer of Malta | Found agglutinins against M. melitensis in Maltese goats’ blood | [20]     |
| 1905 | Themistokles Zammit | Identified Maltese goats’ milk as the source of infection for human brucellosis | [20]     |
| 1957 | Elberg and Faunce | B. melitensis strain Rev. 1 was successfully evaluated as immunogen against caprine brucellosis | [21]     |

Table 1. Dates and major events associated with caprine brucellosis and its relationship with public health throughout history.
tests that would otherwise underpin diagnoses and research. Over the last 15 years, the infection has re-emerged, in particular in Eastern Europe, the Balkans, and Eurasia [2]. Table 2 shows those countries where caprine brucellosis (i.e., presence of anti-Brucella antibodies, B. melitensis isolation, or Brucella DNA detection from goat samples) or brucellosis in humans, sheep, or cattle due to B. melitensis infection have been reported in recent years (2005–present). Historically, B. melitensis biovar 1 is predominant in Latin America [28,33], while biovar 2 is predominant in the Middle East together with biovar 3, which is also more common in European and African Mediterranean countries, Eurasia, and China [2,28,31,34,35]; biovars 1 and 3 seem to be equally present in India [36,37]. Unfortunately, there are few studies addressing the characterization of isolates from sub-Saharan countries.

In the Americas, Brucella melitensis was most likely introduced around the 16th century via the infected goats and sheep of Spanish and Portuguese conquerors [11]. Today, B. melitensis is endemic in some regions of Mexico, Peru, and Argentina [28] and has also been reported in Ecuador and Venezuela [41,48]. Caprine brucellosis is apparently absent in Central America, Bolivia, Paraguay, and Brazil, although this epidemiological situation is not confirmed [129]. Goat herds from the USA, Canada, Colombia, Chile, and Uruguay are free from B. melitensis infection, and human cases in these countries are clearly associated with international travelers or infected food imported from endemic regions [6].

Despite intense joint efforts to eliminate B. melitensis from goat flocks in Europe, the disease still occurs in Portugal, Spain, France, Italy, the Balkans, Bulgaria, and Greece. Northern and Central European countries like the United Kingdom, Belgium, the Netherlands, Denmark, Germany, Austria, Switzerland, the Czech Republic, Hungary, Poland, Romania, Sweden, Norway, and Finland, among others, are officially free of the disease [129].
Table 2. Countries where caprine brucellosis or brucellosis in humans, sheep, or cattle due to *B. melitensis* infection have been reported in recent years (2005–present).

| Country                      | Level of detection                                                                 | Reference(s) |
|------------------------------|------------------------------------------------------------------------------------|---------------|
| **America**                  |                                                                                     |               |
| Argentina                    | Anti-Brucella Ab in goats; isolation of *B. melitensis* bv1 from goats               | [38,39,40]    |
| Bolivia and Brazil           | Mentioned as countries with endemic caprine brucellosis                              | [28]          |
| Ecuador                      | Anti-Brucella Ab in goats; *Brucella* spp. DNA detection in goat milk and LN         | [41]          |
| Mexico                       | Anti-Brucella Ab in goats; isolation of *B. melitensis* from goats                   | [42,43,44]    |
| Paraguay                     | Human case of brucellosis by contact with infected goats: clinical and serological evidence | [45]          |
| Peru                         | Anti-Brucella Ab in goats                                                            | [46,47]       |
| Venezuela                    | Anti-Brucella Ab in goats                                                            | [48]          |
| **Europe**                   |                                                                                     |               |
| Bosnia-Herzegovina           | Anti-Brucella Ab in goats and human                                                  | [49,50]       |
| Bulgaria                     | Anti-Brucella Ab in goats and human                                                  | [51,52]       |
| Croatia                      | Anti-Brucella Ab and isolation of *B. melitensis* bv3 from goats                    | [53]          |
| France                       | Anti-Brucella Ab in goats; isolation of *B. melitensis* bv3 from wild goats         | [54]          |
| Greece                       | Anti-Brucella Ab in goats and human; isolation of *B. melitensis* bv3 from human    | [55]          |
| Italy                        | Isolation of *B. melitensis* bv1 and bv3 from goats                                | [56,57]       |
| Macedonia                    | Anti-Brucella Ab in goats                                                            | [58,59]       |
| Portugal                     | Anti-Brucella Ab in goats                                                            | [60]          |
| Serbia                       | Anti-Brucella Ab in goats and human                                                 | [61]          |
| Spain                        | Anti-Brucella Ab in goats                                                            | [62]          |
| Andorra, Albania, Montenegro, and Cyprus | Mentioned as countries with endemic caprine brucellosis | [28]          |
| **Asia**                     |                                                                                     |               |
| Afghanistan                  | Anti-Brucella Ab in goats and sheep                                                 | [63]          |
| Armenia                      | Anti-Brucella Ab in goats                                                            | [64]          |
| Azerbaijan                   | Anti-Brucella Ab in goats and sheep                                                 | [65]          |
| Bangladesh                   | Anti-Brucella Ab in goats and sheep                                                 | [66]          |
| China                        | Isolation of *B. melitensis*; Anti-Brucella Ab in human                              | [35,67]       |
| Georgia                      | Anti-Brucella Ab in goats; isolation of *B. melitensis* from goats and cattle        | [68,69]       |
| India                        | Anti-Brucella Ab in goats and sheep; isolation of *B. melitensis* bv3 from goats    | [37,70]       |
| Iran                         | Anti-Brucella Ab in goats and sheep; isolation of *B. melitensis* bv1 and 2 from sheep and human | [71,72,73] |
| Iraq                         | Anti-Brucella Ab in sheep and isolation of *B. melitensis* from human               | [74,75]       |
| Israel                       | Anti-Brucella Ab in goats and human; isolation of *B. melitensis* bv1 and 2 from goats | [76]          |
| Jordan                       | Anti-Brucella Ab in goats and isolation of *B. melitensis* bv3 from goat fetus and vaginal fluid | [77,78] |
| Kazakhstan                   | Anti-Brucella Ab in goats and sheep; isolation of *B. melitensis* from blood of sheep | [79,80,81] |
| Kuwait                       | Isolation of *B. melitensis* bv2 from aborted bovine fetus                           | [82]          |
| Kyrgyz Republic and Uzbekistan | Anti-Brucella Ab in goats and sheep                                               | [83]          |
| Lao                          | Anti-Brucella Ab in goats                                                            | [84]          |
| Malaysia                     | Isolation of *B. melitensis* from vaginal fluid and spleen of goats                 | [85]          |
| Mongolia                     | Anti-Brucella Ab in goats and sheep                                                 | [86]          |
| Nepal                        | Anti-Brucella Ab in goats                                                            | [87]          |
| Palestine                    | Anti-Brucella Ab in goats; DNA detection and isolation of *B. melitensis* bv3 from goat milk and fetus | [88,89] |
| Russia                       | Anti-Brucella Ab in goats and sheep                                                 | [90]          |
| Saudi Arabia                 | Anti-Brucella Ab in goats and sheep                                                 | [91]          |
| Syria                        | Anti-Brucella Ab and isolation of *Brucella* spp. in sheep                          | [92]          |
| Tajikistan                   | Anti-Brucella Ab in goats and sheep                                                 | [93]          |
| Thailand                     | Anti-Brucella Ab in goats and sheep                                                 | [94]          |
| Turkey                       | Anti-Brucella Ab in goats and human; isolation of *B. melitensis* from goats        | [95]          |
| UAE                          | Anti-Brucella Ab in goats, sheep and camels                                         | [96,97]       |

(continued)
In Asia, brucellosis is broadly distributed. Except for Japan and the Republic of Korea (South Korea), where the disease has never been reported, caprine brucellosis is officially recognized in several countries on the continent, such as Turkey, Israel, Jordan, Iraq, Iran, Armenia, Georgia, Afghanistan, Russia, and Mongolia, among others (see references in Table 2), and is also known to be endemic in countries like Syria, Lebanon, India, China, Indonesia, Myanmar, etc., where no public information is available or the distribution of the information is restricted [28,29,102,129]. Altogether, the information above indicates that the knowledge regarding distribution of caprine brucellosis as well as the presence of \textit{B. melitensis} around the world is sparse, especially in some areas of the Americas, Asia and Africa. The lack of useful epidemiological data must stimulate official veterinary services and public health officers to collect and share data for designing control and eradication plans.

**Economic impact: Direct and indirect cost in human health and goat production**

Since brucellosis is considered a neglected disease that significantly affects countries where resources are limited, there are only a few studies that measure the economic impact of brucellosis in small ruminants. Sulima and Venkataraman (2010) and Singh et al. (2015) estimated the annual loss in India at Rs. 2,121 per goat (around US$39) and at US$71 million total, respectively.
[131,132]. Brisibe et al. (1996) calculated a loss of US$3.2 million per annum in 2 states of Nigeria [133], and more recently, Bamiyi et al. (2015) reported the annual economic impact in Malaysia due to caprine brucellosis at almost US$2.6 million [134]. However, every publication utilizes different criteria, which makes comparisons difficult. A simple analysis of economic impact of caprine brucellosis on meat goat farmers can be calculated by taking into consideration the culling of animals serologically positive for *Brucella*, the abortions and stillbirths, the cost of veterinary services, and miscellaneous factors arising from brucellosis on farms. The economic loss for culling 1 reactor animal is equal to the market price of a healthy goat purchased for its replacement, minus the amount perceived for selling the positive reactor to a slaughterhouse. An abortion or stillbirth must be considered as loss of profit and its value calculated as the market value of a 6-month-old kid (which weighs around 10 kg). Veterinary services include visits to the farm, professional assistance, and serological surveys, while miscellaneous factors—such as man hours for taking care of ill flocks, reduced weight gain, the increased morbidity of weak offspring and low birth weight kids, any interest paid on money borrowed from banks, etc.—are variable and, therefore, difficult to predict and calculate. Based on these premises, it is possible to roughly estimate the economic impact of a brucellosis outbreak in a meat goat herd. For instance, in Argentina, the impact of a brucellosis outbreak in a flock of 100 goats, in which 25 does abort and 10 others become serologically positive, would be:

A) Replacement of animals (healthy female Creole crossbreed 1-year-old): US$50 each × 35 does = US$1,750
B) Culled animals: US$20 × 35 goats = US$700
C) Six-month-old kids: US$30 each x 25 goats = US$750
D) Veterinary assistance: US$200 (every farm visit)
E) Individual serological tests: US$4 (includes disposables and 1 serological test [Rose Bengal or Fluorescent Polarization assay]) × 100 animals × 2 (2 rounds of survey minimum) = US$800

\[
\text{Economic impact} = \text{US$} \left[ (A - B) + C + D + E \right] \\
= \text{US$} \left[ (1,750 - 700) + 750 + 200 + 800 \right] \\
= \text{US$}2,800
\]

There are some differences if the analysis is done for a dairy goat farm. For instance, the market price of healthy milking goats (Anglo Nubian, Saanen, Toggenburg) is higher than for meat goats, and the loss of milk yield due to culled does has to be taken into account as well. Thus, a conservative impact of a brucellosis outbreak in a herd of 100 milk goats, in which 25 does abort and 10 others become serologically positive, would be:

A) Replacement of animals (healthy 1-year-old female): US$100 × 35 does = US$3,500
B) Culled animals: US$20 × 35 goats = US$700
C) Lower milk yield: US$4/L of milk farm sale × 500 L/lactation period × 35 culled animals = US$70,000
D) Veterinary assistance: US$200 (every farm visit) × 3 = US$600
E) Individual serological tests: US$4 (include disposables and 1 serological test [Rose Bengal or Fluorescent Polarization assay]) × 100 animals × 3 (3 rounds of survey minimum) = US$1,200

Economic impact = US$ [(A – B) + C + D + E]

= US$ [(3,500 – 700) + 70,000 + 600 + 1,200]

= US$74,600

The estimated cost will vary with the location, production system, facilities, and miscellaneous factors included. The calculations need to include additional losses due to the socioeconomic and indirect health effects of the disease in humans. Still today, human brucellosis is an underreported disease, often mistaken for malaria and typhoid fever (Halliday et al., 2015). WHO estimates around 500,000 new cases reported and an equal number of nonreported cases of human brucellosis each year, a high proportion of them caused by B. melitensis. Vulnerable populations include not only dairy goat and sheep farmers, small ruminant ranchers (especially in marginalized goat-keeping communities), and veterinarians and abattoir workers, but also lab personnel and consumers of unpasteurized dairy products.

Economic losses caused by the disease in humans arise from the cost of hospital treatment, medicines, patient out-of-pocket treatment expenses, and loss of work days and income due to illness. In Spain, losses by brucellosis were estimated at 790,000 pesetas per patient (US$5,030) [135], while in New Zealand, the approximated cost per patient was NZ$3,200 (US$2,250) [136]. In Africa, the cost of treating a patient ranges from 9 EUR in Tanzania to 200 EUR in Morocco and as much as 650 EUR in Algeria [128]. In Argentina, the annual treatment cost of brucellosis was estimated to be US$4,000 [137].

Traditional recommended antibiotic treatment for human brucellosis consists of 100 mg of doxycycline twice a day per os for 45 days combined with 1 g of streptomycin daily intramuscular (IM), 15 to 21 days; gentamycin 5 mg/kg/day (300–350 mg) IM, 7 to 10 days; or, alternatively, rifampicin 15mg/kg/day (600–900 mg) per os for 45 days [3]. Today, in Argentina, the cost for antibiotic treatment for a single patient is approximately US$200–US$300. This value does not include lost profit, laboratory analysis and X-ray images, medical expenses, and other miscellaneous expenses. Considering a complete health treatment, the cost for every brucellosis-infected person is up to US$1,000.

Conclusions and future approaches

Brucellosis in small ruminants remains a significant burden on animal and human health in the developing world. Small ruminant owners and governments where brucellosis is endemic do not usually have enough economic resources nor technical expertise or facilities to afford control or eradication campaigns. On the other hand, B. melitensis is the Brucella species with the highest zoonotic potential, and in humans, it frequently presents nonspecific clinical symptoms similar to other infectious diseases that are also present in brucellosis-endemic areas [138]. Thus, the challenge of clinical–differential diagnosis adds to the inequality of accessible healthcare facilities in most developing countries. These cumulative issues contribute to brucellosis remaining endemic and neglected in resource-limited regions of the world.

The future major challenges include developing a more effective and affordable DIVA (differentiating infected from vaccinated animals) vaccine against small ruminant brucellosis for massive protection in endemic areas. Undoubtedly, this goal must be accompanied by an integrated control strategy with a massive vaccination campaign, strict epidemiological surveillance,
and controlled movement of animals. Meanwhile, current efforts must focus on controlling new outbreaks using available tools to prevent *B. melitensis* transmission to humans.

**Key learning points**

- *Brucella melitensis* is the etiological agent of caprine brucellosis and the species of the *Brucella* genus with the highest zoonotic potential.
- Lesions in vertebral bodies consistent with brucellosis were found in an *Australopithecus africanus*, an ancient human who lived 2.5 million years ago.
- The disease remains a significant burden on goats and human health in the Mediterranean region, the Middle East, Central and Southeast Asia (including India and China), sub-Saharan Africa, and parts of Latin America.
- *B. melitensis* comprises 3 biovars (1–3): biovar 1 is predominant in Latin America, biovar 2 is predominant in the Middle East, and biovar 3 is also present in Middle East and also in European and African Mediterranean countries, Eurasia, and China. Biovars 1 and 3 seem to be equally present in India.
- The economic impact of a brucellosis outbreak is higher in milk-than in meat-producing farms.

**Top five papers**

1. Benkirane A (2006) Ovine and caprine brucellosis: World distribution and control / eradication strategies in West Asia / North Africa region. Small Ruminant Research 62: 19–25.
2. Bruce D (1893) Sur une nouvele forme de fievre. Annales de l’Institut Pasteur 7: 289–304.
3. FAO. *Brucella melitensis* en Eurasia and the Middle East. In: FAO, editor; 2010; Rome, Italy. pp. 57 pp.
4. Foster JT, Beckstrom-Sternberg SM, Pearson T, Beckstrom-Sternberg JS, Chain PS, et al. (2009) Whole-genome-based phylogeny and divergence of the genus Brucella. J Bacteriol 191: 2864–2870.
5. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV (2006) The new global map of human brucellosis. Lancet Infect Dis 6: 91–99.

**Acknowledgments**

The authors want to thank to Dr. L. Garry Adams for his critical review and thoughtful suggestions on the manuscript and Mr. Matias Ottaviani for helping us with the illustration.
References

1. Tosser-Klopp G, Bardou P, Bouchez O, Cabau C, Crooijmans R, et al. Design and characterization of a 52K SNP chip for goats. PLoS ONE. 2014; 9: e86227. https://doi.org/10.1371/journal.pone.0086227 PMID: 24465974

2. FAO. Brucella melitensis en Eurasia and the Middle East. In: FAO, editor; 2010; Rome, Italy. pp. 57 pp.

3. Corbel MJ. Brucellosis in humans and animals. Geneva, Switzerland: World Health Organization. 2006. 89 p.

4. Nelson-Jones A. Brucellosis. Postgrad Medical J. 1952; 28: 529–534.

5. Pappas G, Papanopoulos P, Christou L, Akritidis N. Brucella as a biological weapon. Cell Mol Life Sci. 2006; 63: 2229–2236. https://doi.org/10.1007/s00018-006-6311-4 PMID: 16964579

6. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006; 6: 91–99. https://doi.org/10.1016/S1473-3099(06)70382-6 PMID: 16439239

7. Capasso L. Bacteria in two-millennia-old cheese, and related epizoonoses in Roman populations. J Infect. 2002; 45: 122–127. PMID: 12217720

8. Foster JT, Beckstrom-Sternberg SM, Pearson T, Beckstrom-Sternberg JS, Chain PS, et al. Whole-genome-based phylogeny and divergence of the genus Brucella. J Bacteriol. 2009; 191: 2864–2870. https://doi.org/10.1128/JB.01581-08 PMID: 19201792

9. D’Anastasio R, Zipfel B, Moggi-Cecchi J, Stanyon R, Capasso L. Possible brucellosis in an early hominin skeleton from sterkfontein, South Africa. PLoS ONE. 2009; 4: e6439. https://doi.org/10.1371/journal.pone.0006439 PMID: 19649274

10. Zeder MA, Hesse B. The initial domestication of goats (Capra hircus) in the Zagros mountains 10,000 years ago. Science. 2000; 287: 2254–2257. PMID: 10731145

11. Pereira F, Amorim A. Origin and spread of goat pastoralism. Encyclopedia of Life Science. Chichester, UK: John Wiley & Sons, Ltd. 2010.

12. Alton GG. Brucella melitensis. In: Nielsen K, Duncan JR, editors. Animal brucellosis. Boca Raton, Florida, USA: CRC Press, Inc. 1990. pp. 383–409.

13. Garcia-Carrillo C. La brucelosis de los animales en América y su relación con la infección humana. Paris, France: OIE. 1987. 303 p.

14. Eyre JWH. Melitensis septicaemia. Lancet. 1908; 1: 1677–1682.

15. Vassallo DJ. The Corps Disease: Brucellosis and Its Historical Association with the Royal Army Medical Corps J R Army Med Corps. 1992; 138: 140–150. PMID: 1453384

16. Marston JA. Report on Fever (Malta). London: Army Medical Department. 1863; 486–521 p.

17. Bruce D. Note on the discovery of a micro-organism in Malta fever. The Practitioner. 1887; 39: 161–170.

18. Bruce D. Sur une nouvelle forme de fièvre. Ann de l’Institut Pasteur. 1893; 7: 289–304.

19. Wright AE, Smith F. On the application of the serum test to the differential diagnosis of typhoid and Malta fever. Lancet. 1897; 149: 656–659.

20. Wyatt HV. How Themistocles Zammit found Malta Fever (brucellosis) to be transmitted by the milk of goats. J Royal Soc Med. 2005; 98: 451–454.

21. Elberg SS, Faunce K. Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. J Bacteriol. 1957; 73: 211–217. PMID: 13416171

22. Ali S, Akhter S, Neubauer H, Melzer F, Khan I, et al. Serological, cultural, and molecular evidence of Brucella infection in small ruminants in Pakistan. J Infect Dev Ctries. 2015; 9: 470–475. https://doi.org/10.3855/jidc.5110 PMID: 25989166

23. Leal-Klevezas DS, Martinez-Vazquez JO, Garcia-Cantu J, Lopez-Merino A, Martinez-Soriano JP. Use of polymerase chain reaction to detect Brucella abortus biovar 1 in infected goats. Vet Microbiol. 2000; 75; 91–97. PMID: 10865155

24. Wareth G, Melzer F, Tomaso H, Reesler U, Neubauer H. Detection of Brucella abortus DNA in aborted goats and sheep in Egypt by real-time PCR. BMC Res Notes. 2015; 8: 212. https://doi.org/10.1186/s13104-015-1173-1 PMID: 26036697

25. Bhaskar Rao P, Madhubala K, Ramakrishna Rao M. Prevalence of viral and bacterial diseases among goats in Andhra Pradesh. Indian Vet J. 1998; 75; 924–925.
26. Alton GG, Jones LM, Angus RD, Verger J-M. Techniques for the brucellosis laboratory. Paris, France: Institut National de la Recherche Agronomique. 1988.

27. Jiang H, Wang H, Xu L, Hu G, Ma J, et al. MLVA genotyping of Brucella melitensis and Brucella abortus isolates from different animal species and humans and identification of Brucella suis vaccine strain S2 from cattle in China. PLoS ONE. 2013; 8: e76332. https://doi.org/10.1371/journal.pone.0076332 PMID: 24124546

28. Benkirane A. Ovine and caprine brucellosis: World distribution and control / eradication strategies in West Asia / North Africa region. Small Rum Res. 2006; 62: 19–25.

29. Gwida M, Al Dahouk S, Melzer F, Rosler U, Neubauer H, et al. Brucellosis—regionally emerging zoonotic disease? Croat Med J. 2010; 51: 289–295. https://doi.org/10.3325/cmj.2010.51.289 PMID: 20718081

30. McDermott JJ, Arimi SM. Brucellosis in sub-Saharan Africa: epidemiology, control and impact. Vet Microbiol. 2002; 90: 111–134. PMID: 12414138

31. Musallam II, Abo-Shehada MN, Hegazy YM, Holt HR, Guitian FJ. Systematic review of brucellosis in the Middle East: disease frequency in ruminants and humans and risk factors for human infection. Epidemiol Infect. 2016; 144: 671–685. https://doi.org/10.1017/S0950268815002575 PMID: 26508323

32. Racloz V, Schelling E, Chitnis N, Roth F, Zinsstag J. Persistence of brucellosis in pastoral systems. Rev Sci Tech. 2013; 32: 61–70. PMID: 23837365

33. Lucero NE, Ayala SM, Escobar GI, Jacob NR. Brucella isolated in humans and animals in Latin America from 1968 to 2006. Epidemiol Infect. 2008; 136: 496–503. https://doi.org/10.1017/S0950268807008795 PMID: 17559694

34. Refai M. Incidence and control of brucellosis in the Near East region. Vet Microbiol. 2002; 90: 81–110. PMID: 12414137

35. Sun MJ, Di DD, Li Y, Zhang ZC, Yan H, et al. Genotyping of Brucella melitensis and Brucella abortus strains currently circulating in Xinjiang, China. Infect Genet Evol. 2016; 44: 522–529. https://doi.org/10.1016/j.meegid.2016.07.025 PMID: 27521159

36. Barua A, Abo-Shehada MN, Hegazy YM, Holt HR, Guitian FJ. Systematic review of brucellosis in the Middle East: disease frequency in ruminants and humans and risk factors for human infection. Epidemiol Infect. 2016; 144: 671–685. https://doi.org/10.1017/S0950268815002575 PMID: 26508323

37. Singh A, Gupta VK, Kumar A, Singh VK, Nayakwadi S. 16S rRNA and omp31 gene based molecular characterization of field strains of B. melitensis from aborted foetus of goats in India. Scientific World J. 2013: 160376.

38. Russo AM, Mancebo OA, Monzón CM, Gait JJ, Casco RD, et al. Epidemiología de la brucelosis caprina y ovina en la provincia de Formosa, Argentina. Rev Arg Microbiol. 2016; 48: 147–153.

39. Gaido A, Salatin A, Neumann R, Marinconz R, Rossetto C, et al. Goat brucellosis: a serological study in flocks from the east of Salta, Argentina. In: Microbiologia AAd, editor. Brucellosis 2011 International Research Conference. Buenos Aires, Argentina. 2011. pp. 140 pp.

40. Robles C, Bernard O, Zenocrati L, Marcellino R. Encuesta serológica sobre brucelosis en la provincia de Mendoza. Vet Arg. 2007; 24: 172–185.

41. Poulsen KP, Hutchins FT, McNulty CM, Tremblay M, Zabala C, et al. Brucellosis in dairy cattle and goats in northern Ecuador. Am J Trop Med Hyg. 2014; 90: 712–715. https://doi.org/10.4269/ajtmh.13-0362 PMID: 24591429

42. Osegueda Montiel D, Franken K, Udo H, Keilbach Baer NM, van der Zijpp A. Prevalence and risk factors for brucellosis in goats in areas of Mexico with and without brucellosis control campaign. Trop Anim Health Prod. 2013; 45: 1383–1389. https://doi.org/10.1007/s11250-013-0375-6 PMID: 23420068

43. Herrera E, Rivera A, Palomares EG, Hernandez-Castro R, Diaz-Aparicio E. Isolation of Brucella melitensis from a RB51-vaccinated seronegative goat. Trop Anim Health Prod. 2011; 43: 1069–1070. https://doi.org/10.1007/s11250-011-9822-4 PMID: 21455694

44. Solorio-Rivera JL, Segura-Correia JC, Sanchez-Gil LG. Seroprevalence of and risk factors for brucellosis of goats in herds of Michoacan, Mexico. Prev Vet Med. 2007; 82: 282–290. https://doi.org/10.1016/j.prevetmed.2007.05.024 PMID: 17604858

45. Dietz Sanchez E, Escríbá Berro D. Artritis como forma de presentación de brucelosis. Reporte de un caso. Pediatr (Asunción). 2005; 32: 30–34.

46. Taboada N, Campos M, Leiva L, Gómez J, Mansilla C, et al. Seroprevalencia de brucelosis en ganado caprino en el Callao, Perú. Rev Peru Med Exp Salud Publica. 2005. 22: 139–144.

47. Toledo M, Delgado A, Suárez F, Noé N. Prevalencia de brucelosis caprina en tres distritos de la provincia de Cañete, Lima. Rev Inv Vet Peru. 2007; 18: 136–140.
48. Javitt J. M, Paez Z, Duran J, Melendez I. Seroprevalencia de la brucelosis en pequeños rumiantes. Municipio Torres. Año 2008. REDVET Rev Electr Vet Spain. 2009. Veterinaria Organizacion.

49. Nedelc DN, Mehmedbasic Z, Hadzovic D, Trkuljija R. Implementation of disease control measures for brucellosis of small ruminants in Bosnia and Herzegovina for the period January 2009-December 2010 In: Microbiologia AAd, editor. Brucellosis 2011 International Research Conference. Buenos Aires, Argentina. 2011. pp. 140 pp.

50. Obradovic Z, Velic R. Epidemiological characteristics of brucellosis in Federation of Bosnia and Herzegovina. Croat Med J. 2010; 51: 345–350. https://doi.org/10.3325/cmj.2010.51.345 PMID: 20718088

51. Likov B, Nenova-Poliakova R, Tomova I, Kamenov P, Boikovski I, et al. Epidemiological characteristics of brucellosis in sheep and goats in Bulgaria: 2005–2008. Prilozi. 2010; 31: 55–64. PMID: 20703183

52. Nenova R, Tomova I, Saparevskia R, Kantardjieva T. A new outbreak of brucellosis in Bulgaria detected in July 2015—preliminary report. Euro Surveill. 2015; 20 (39) pii:30031.

53. Spicic S, Zdelar-Tuk M, Racic I, Duvnjak S, Cvetnic Z. Serological, bacteriological, and molecular diagnosis of brucellosis in domestic animals in Croatia. Croat Med J. 2010; 51: 320–326. https://doi.org/10.3325/cmj.2010.51.320 PMID: 20718085

54. Mick V, Le Carrou G, Corde Y, Game Y, Jay M, et al. Brucella melitensis in France: persistence in wildlife and probable spillover from Alpine ibex to domestic animals. PLoS ONE. 2014; 9: e94168. https://doi.org/10.1371/journal.pone.0094168 PMID: 24732322

55. Karagiannis I, Mellou K, Douglas G, Theocharopoulos G, Vourvidis D, et al. Outbreak investigation of brucellosis in Thassos, Greece, 2008. Euro Surveill. 2012; 17: pii = 20116.

56. De Massis F, Ancora M, Atzeni M, Rolesu S, Bandino E, et al. MLVA as an Epidemiological Tool To Trace Back Brucella melitensis Biovar 1 Re-Emergence in Italy. Transbound Emerg Dis. 2015; 62: 463–469. https://doi.org/10.1111/tbed.12397 PMID: 26194658

57. Di Giannatale E, De Massis F, Ancora M, Zilli K, Alessiani A. Typing of Brucella field strains isolated from livestock populations in Italy between 2001 and 2006. Vet Ital. 2008; 44: 383–388. PMID: 20405440

58. Naletoski I, Kirandziski T, Mitrov D, Krstevski K, Dzadzovski I, et al. Gaps in brucellosis eradication campaign in sheep and goats in Republic of Macedonia: lessons learned. Croat Med J. 2010; 51: 351–356. https://doi.org/10.3325/cmj.2010.51.351 PMID: 20718089

59. Kirandjiski T, Nikolovska G, Nakova E, Smilenovska B, Strojmanovska B, et al. Brucellosis control in small ruminants in the Republic of Macedonia. Prilozi. 2010; 31: 181–190. PMID: 20703191

60. Coelho AM, Coelho AC, Rodrigues J. Seroprevalence and sheep and goat brucellosis in the north-east of Portugal. Arch Med Vet. 2013; 45: 167–172.

61. Markovic-Denic L, Trifunovic VS, Zugic V, Radojc D, Stevanovic. The first outbreak of brucellosis in the region of Sabac. Vojnosanit Pregl. 2010; 67: 634–637. PMID: 20845665

62. Alvarez J, Saez JL, Garcia N, Serrat C, Perez-Sancho M, et al. Management of an outbreak of brucellosis due to B. melitensis in dairy cattle in Spain. Res Vet Sci. 2011; 90: 208–211. https://doi.org/10.1016/j.rvsc.2010.05.028 PMID: 20579679

63. Hussain A, Ghulam Z, Rasuli AB, Schauwers W, Dennison T, et al. Seroprevalence survey of animal brucellosis in Afghanistan. In: Assessment FIfR, editor. Brucellosis 2014 International Research Conference. Berlin, Germany. 2014; pp. 226 pp.

64. Porphryre T, Jackson R, Sauter-Louis C, Ward D, Baghyan G, et al. Mapping brucellosis risk in communities in the Republic of Armenia. Geospatial Health. 2010; 5: 103–118. https://doi.org/10.4081/gh.2010.191 PMID: 21080325

65. Omarov AM, Jackson R, Brant J, Rush T, Maes E. The new brucellosis surveillance system in Azerbaijan. In: Microbiologia AAd, editor. Brucellosis 2011 International Research Conference. Buenos Aires, Argentina. 2011. pp. 140 pp.

66. Islam MA, Khattun MM, Werre SR, Siriranganathan N, Boyle SM. A review of Brucella seroprevalence among humans and animals in Bangladesh with special emphasis on epidemiology, risk factors and control opportunities. Vet Microbiol. 2013; 166: 317–326. https://doi.org/10.1016/j.vetmic.2013.06.014 PMID: 23867082

67. Li YJ, Li XL, Liang S, Fang LQ, Cao WC. Epidemiological features and risk factors associated with the spatial and temporal distribution of human brucellosis in China. BMC Infect Dis. 2013; 13: 547. https://doi.org/10.1186/1471-2334-13-547 PMID: 24238301

68. Duran-Ferrer M, Avallani L, Chumburidze K, Pacios A, Eldrissi A, et al. Assessment of brucellosis epidemiology in the Republic of Georgia and proposal of sustainable prevention and control In: Assessment FIfR, editor. Brucellosis 2014 International Research Conference. Berlin, Germany. 2014; pp. 226 pp.
69. Mamisashvili E, Kracalik IT, Onashvili T, Kerdze vadze L, Goginashvili K, et al. Seroprevalence of brucellosis in livestock within three endemic regions of the country of Georgia. Prev Vet Med. 2013; 110: 554–557. https://doi.org/10.1016/j.prevetmed.2012.12.005 PMID: 23287714

70. Sadhu DB, Panchasara HH, Chauhan HC, Sutariya DR, Parmar VL, et al. Seroprevalence and comparison of different serological tests for brucellosis detection in small ruminants. Vet World. 2015; 8: 561–566. https://doi.org/10.14202/vetworld.2015.561-566 PMID: 27047135

71. Akbarmehr J, Ghiyamirad M. Serological survey of brucellosis in livestock animals in Sarab City (East Azarbayjan province), Iran. African J Microbiol Res. 2011; 5: 1202–1203.

72. Pishva E, Salehi R, Hoseini A, Kargar A, Taba FE, et al. Molecular typing of Brucella species isolates from Human and livestock bloods in Isfahan province. Adv Biomed Res. 2015; 4: 104. https://doi.org/10.4103/2277-9175.157798 PMID: 26261806

73. Bechtol D, Carpenter LR, Mosites E, Smalley D, Dunn JR. Brucella melitensis infection following military duty in Iraq. Zoonoses Public Health. 2011; 58: 489–492. https://doi.org/10.1111/j.1863-2378.2011.01399.x PMID: 21824352

74. Al-Tae AH, Al-Samarraie EA. Detection of Brucella antibodies of sheep in Al-Anbar province by using some serological tests. Iraqi J Vet Med. 2013; 37: 7–12.

75. Armon L, Hadani Y, Chechik C, Bardenstein S. Large human Brucella melitensis outbreak in Israel, 2014. Israel J Vet Med. 2015; 70: 63–65.

76. Wolfram JH, Butaev MK, Dyuysheev A, Gabbasova AR, Khasanov OS, et al. Epidemiology chapter. Vaccine. 2010; 28 Suppl 5: F77–84.

77. Shevtsov A, Ramanculov E, Shevtsova E, Kairzhanova A, Tarlykov P, et al. Genetic diversity of Brucella abortus and Brucella melitensis in Kazakhstan using MLVA-16. Infect Genet Evol. 2015; 34: 173–180. https://doi.org/10.1016/j.meegid.2015.07.008 PMID: 26160544

78. El Bayoumy I, Azmi H. Study of epidemiological features of Brucellosis in Kuwait. Global Res J Pub Health Epidemiol. 2014; 1: 23–30.

79. Pandeya YR, Joshi DD, Dhakal S, Ghimire L, Mahato BR, et al. Seroprevalence of brucellosis in different animal species of Kailali district, Nepal. Intern J Infect Microbiol. 2013; 2: 22–25.

80. Din AMU, Khan SA, Ahmad I, Rind R, Hussain T, et al. A study on the seroprevalence of brucellosis in human and goat populations of district Bhimber, Azad Jammu and Kashmir. J Anim Plant Sci. 2013; 23: 113–118.

81. Arshad M, Munir M, Khan HJ, Abbas RZ, Rasool MH, et al. Seroprevalence of brucellosis in goats from public and private livestock farms in Pakistan. J Vet Res. 2011; 15: 297–304.

82. Awwad E, Farrag MA, Adwan K, Essawi TA. Isolation, identification and molecular characterization of Brucella strains isolated from small ruminants in the West Bank, Palestine. Revue Med Vet. 2011; 162: 236–239.
91. Hawari AD. Epidemiological studies, seroprevalence and some risk factors of brucellosis in sheep and goats in the South Province of West Bank. Asian J Anim Vet Adv. 2012; 7: 535–539.

92. Kulakov YK, Novikova MD, Sklyarov OD. Epidemiological status of brucellosis in the Russian Federation. In: Assessment FIIR, editor. Brucellosis 2014 International Research Conference. Berlin, Germany. 2014; pp. 226 pp.

93. Kandeel AE, Gamal TM, Sediek AA, Salauddin HS, Fadlelmoula AA. Seroprevalence of Brucellosis within sheep and goat flocks in Alkamil province in Saudi Arabia. Bothalia J. 2014; 44: 131–140.

94. Al-Mariri A, Ramadam L, Akel R. Assessment of milk ring test and some serological tests in the detection of Brucella melitensis in Syrian female sheep. Trop Anim Health Prod. 2011; 43: 865–870. https://doi.org/10.1007/s11250-010-9774-0 PMID: 21234678

95. Rajala EL, Grahn C, Ljung I, Sattorov N, Boqvist S, et al. Prevalence and risk factors for Brucella seropositivity among sheep and goats in a peri-urban region of Tajikistan. Trop Anim Health Prod. 2016; 48: 553–558. https://doi.org/10.1007/s11250-015-0992-3 PMID: 26779709

96. Ekgatat M, Tiensin T, Kanitpun R, Buamithup N, Jenpanich C, et al. Brucellosis control and eradication programme in Thailand. Preliminary evaluation of the epidemiological situation in cattle, buffaloes and sheep and goats. In: Microbiologia AAa, editor. Brucellosis 2011 International Research Conference. Buenos Aires, Argentina. 2011; pp. 140 pp.

97. Te-Chanyom Y, Geatera AF, Kongkaew W, Chethanonda U, Chongsuvivatwong V. Goat farm management and Brucella serological test among goat keepers and livestock officers, 2011–2012, Nakhon Si Thammarat Province, southern Thailand. One Health. 2016; 2: 126–130. https://doi.org/10.1016/j.onehlt.2016.08.001 PMID: 28616486

98. Yumuk Z, O’Callaghan D. Brucellosis in Turkey—an overview. Int J Infect Dis. 2012; 16: e228–235. https://doi.org/10.1016/j.ijid.2011.12.011 PMID: 22333223

99. Erdenlig S, Baklan EA, Saytekin AM, Saglam G, Karagul MS. The identification of Brucella strains isolated during mass vaccination campaign with B. melitensis Rev1 and B. abortus S19 vaccines in Turkey. In: Assessment FIIR, editor. Brucellosis 2014 International Research Conference. Berlin, Germany. 2014. pp. 226 pp.

100. Gul ST, Khan A. Epidemiology and epizootology of brucellosis: A review Pakistan Vet J. 2007; 27: 145–151.

101. Mohammed MA, Shigidy MT, Al Juboori AY. Sero-prevalence and epidemiology of brucellosis in camels, sheep and goats in Abu Dhabi Emirate. Int J Anim Vet Adv. 2013; 5: 82–86.

102. Bammamay PH, Hassan I, Khairani-Bejo S, Zainal AM. Updates on brucellosis in Malaysia and Southeast Asia. Malaysian J Vet Res. 2014; 5: 71–82.

103. El Tahir YEH, Nair RR. Prevalence of brucellosis in the Sultanate of Oman with reference to some Middle-East countries. Vet Res. 2011; 4: 71–76.

104. Lounes N, Bouyoucef A, Garin-Bastuji B. Bovine and caprine brucellosis in the central region of Algeria. In: Microbiologia AAa, editor. Brucellosis 2011 International Research Conference. Buenos Aires, Argentina. 2011; pp. 140 pp.

105. Gabri A, Agabou A, Gabli Z. Brucellosis in nomadic pastoralists and their goats in two provinces of the eastern Algerian high plateaus. Trop Anim Health Prod. 2015; 47: 1043–1048. https://doi.org/10.1007/s11250-015-0825-4 PMID: 25877260

106. Hegazy YM, Moawad A, Osman S, Ridler A, Guitian J. Ruminant brucellosis in the Kafr El Sheikh Governorate of the Nile Delta, Egypt: prevalence of a neglected zoonosis. PLoS Negl Trop Dis. 2011; 5: e944. https://doi.org/10.1371/journal.pntd.0000944 PMID: 21264355

107. Wareth G, Melzer F, Elschner MC, Neubauer H, Roesler U. Detection of Brucella melitensis in bovine milk and milk products from apparently healthy animals in Egypt by real-time PCR. J Infect Dev Ctries. 2014; 8: 1339–1343. https://doi.org/10.3855/jidc.4847 PMID: 25313613

108. Asmare K, Megersa B, Denbagra Y, Abebe G, Taye A, et al. A study on seroprevalence of caprine brucellosis under three livestock production systems in southern and central Ethiopia. Trop Anim Health Prod. 2013; 45: 555–560. https://doi.org/10.1007/s11250-012-0258-2 PMID: 22961233

109. Sintayehu G, Melesse B, Abayneh D, Sintayehu A, Melaku S, et al. Epidemiological survey of brucellosis in sheep and goats in selected pastoral and agro-pastoral lowlands of Ethiopia. Rev Sci Tech. 2015; 34: 881–893. PMID: 27044159

110. Jarikre TA, Emikpe BO, Folitse RD, Odoom TK, Fuseini A, et al. Prevalence of brucellosis in small ruminants in three regions of Ghana. Bulgarian J Vet Med. 2015; 18: 49–55.

111. Osoro EM, Munyua P, Omulo S, Ogola E, Ade F, et al. Strong Association Between Human and Animal Brucella Seropositivity in a Linked Study in Kenya, 2012–2013. Am J Trop Med Hyg. 2015; 93: 224–231. https://doi.org/10.4269/ajtmh.15-0113 PMID: 26101275
112. Ahmed MO, Elmeshri SE, Abuzweda AR, Blauo M, Abouzeed YM, et al. Seroprevalence of brucellosis in animals and human populations in the western mountains region in Libya, December 2006-January 2008. Euro Surveill. 2010; 15 (30) pii:19625.

113. Benkirane A, Essamkaoui S, El Idriessi A, Luccione L, Natale A. A sero-survey of major infectious causes of abortion in small ruminants in Morocco. Vet Ital. 2015; 51: 25–30. https://doi.org/10.12834/VetIt.389.1814.1 PMID: 25842210

114. Magwedere K, Bishi A, Tijpuza-Zaie G, Eberle G, Hemberger Y, et al. Brucellae through the food chain: the role of sheep, goats and springbok (Antidorcus marsupialis) as sources of human infections in Namibia. J S Afr Vet Assoc. 2011; 82: 205–212. PMID: 22616433

115. Boukary AR, Saegerman C, Abatih E, Fretin D, Alambeji Bada R, et al. Seroprevalence and potential risk factors for Brucella spp. infection in traditional cattle, sheep and goats reared in urban, periurban and rural areas of Niger. PLoS ONE. 2013; 8: e83175. https://doi.org/10.1371/journal.pone.0083175 PMID: 24358261

116. Ogugua AJ, Akinseye VO, Ayoola MC, Oyesola OO, Shima FK, et al. Seroprevalence and risk factors of brucellosis in goats in selected states in Nigeria and the public health implications. Afr J Med Sci. 2014; 43: 121–129. PMID: 26689681

117. Kalungo BY, Saidu SN, Sackey AK, Kazeem HM. Serological evidence of brucellosis in goats in kaduna north senatorial district of kaduna state, Nigeria. ISRN Vet Sci 2013: 963673. https://doi.org/10.1155/2013/963673 PMID: 23762594

118. Hassan-Kadile AA. A review on ruminant and human brucellosis in Somalia. Open J Vet Med. 2015; 5: 133–137.

119. Wojno JM, Moodley C, Plenaar J, Beylis N, Jacobsz L, et al. Human brucellosis in South Africa: Public health and diagnostic pitfalls. S Afr Med J. 2016; 106: 883–885. https://doi.org/10.7196/SAMJ.2016.v106i.11020 PMID: 27601111

120. Ahmed SI, Musa MT. Prevalence of Ovine Brucellosis and Isolation of Brucella melitensis biovar 1 in South Kordofan State, Sudan. Sudan J Vet Res. 2015; 30: 19–23.

121. Musa MT. Caprine Brucellosis under Different Husbandry Systems in Darfur States, Sudan. Sudan J Vet Res. 2006; 21: 57–66.

122. Zein AM, Adris MA. Seroprevalence of brucellosis in different animals species in northern state (Sudan). ARPN J Sci Technol. 2015; 5: 210–214.

123. Assenga JA, Matemba LE, Muller SK, Malakalanga JJ, Kazwala RR. Epidemiology of Brucella infection in the human, livestock and wildlife interface in the Katavi-Rukwa ecosystem, Tanzania. BMC Vet Res. 2015; 11: 189. https://doi.org/10.1186/s12917-015-0504-8 PMID: 26253151

124. Chota AC, Magwisha HB, Stella B, Bunuma BK, Shimira GM, et al. Prevalence of brucellosis in livestock and incidences in humans in east Africa. African Crop Sci J. 2016; 24: 45–52.

125. Grace AK, Jescsa N, Aciej J, Nyakarahuka L. Investigation of the risk factors to human brucellosis in Mubende district, Uganda. In: Assessment FIfR, editor. Brucellosis 2014 International Research Conference. Berlin, Germany. 2014; pp. 226 pp.

126. Miller R, Nakavuma JL, Ssajjakambwe P, Vudriko P, Musisi N, et al. The Prevalence of Brucellosis in Cattle, Goats and Humans in Rural Uganda: A Comparative Study. Transbound Emerg Dis. 2015; 63: e197–e210. https://doi.org/10.1111/tbed.12332 PMID: 25660343

127. Matopse G, Bhebhe E, Muma JB, Skjerve E, Dijonne B. Characterization of some Brucella species from Zimbabwe by biochemical profiling and AMOS-PCR. BMC Res Notes. 2009; 2: 261. https://doi.org/10.1186/1756-0500-2-261 PMID: 20028545

128. Akakpo AJ, Teko-Agbo A, Koné P. The impact of brucellosis in the economy and public health of Africa. 18th Conference of the OIE Regional Commission for Africa. N’Djamena, Tchad. 2009; pp. 85–98.

129. OIE World Animal Health Information Database—Version: 1.4. World Animal Health Information Database. Paris, France. 2009.

130. OIE World Animal Health Information Database. Version 2. World Animal Health Information Database. Paris, France. OIE. 2012.

131. Singh BB, Dhand NK, Gill JP. Economic losses occurring due to brucellosis in Indian livestock populations. Prev Vet Med. 2015; 119: 211–215. https://doi.org/10.1016/j.prevetmed.2015.03.013 PMID: 25835775

132. Sulima M, Venkataraman KS. Economic losses due to Brucella melitensis infection in sheep and goat. Tamilnud J of Vet An Sci. 2010; 6: 191–192.

133. Brisibe F, Nawathe DR, Bot CJ. Sheep and goat brucellosis in Borno and Yobe states of arid Northeastern Nigeria. Small Rum Res. 1996; 20: 83–88.
134. Bamaiyi PH, Khairani-Bejo S, Zainal Abidin M. The economic impact attributable to brucellosis among goat farms in Peninsula Malaysia and cost benefit analysis. Res Opin Anim Vet Sci. 2015; 5: 57–64.

135. Colmenero Castillo JD, Cabrera Franquelo FP, Hernandez Marquez S, Reguera Iglesias JM, Pinedo Sanchez A, et al. [Socioeconomic effects of human brucellosis]. Rev Clin Esp. 1989; 185: 459–463. PMID: 2623280

136. Shepherd AA, Simpson BH, Davidson RM. An economic evaluation of the New Zealand bovine brucellosis eradication scheme. In: Geering WA, Roe RT, Chapman LA, editors; 1979 7–11 May 1979; Canberra, Australia. The Australian Government Publishing Services. pp. 443–447.

137. Pandolfo GP, Petri NM, Lasta HC, Petigiani ER. Brucelosis en el medio rural de la República Argentina. Tesis para optar al premio de la Academia Nacional de Medicina. Buenos Aires, Argentina. 1976.

138. Halliday JEB, Allan KJ, Ekwem D, Cleaveland S, Kazwala RR, et al. Endemic zoonoses in the tropics: A public health problem hiding in plain sight. Vet Rec. 2015; 176: 220–225. https://doi.org/10.1136/vr.h798 PMID: 2572334